- Home
- PRT vs NSRX Comparison
PRT vs NSRX Comparison
Compare PRT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | NSRX |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 52.5M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | PRT | NSRX |
|---|---|---|
| Price | $3.46 | $5.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 55.5K | 4.5K |
| Earning Date | 03-27-2026 | 03-20-2026 |
| Dividend Yield | ★ 12.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $6,009,225.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.61 | $4.90 |
| 52 Week High | $4.63 | $9.99 |
Technical Indicators
Market Signals| Indicator | PRT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 39.97 |
| Support Level | $3.29 | $4.90 |
| Resistance Level | $3.75 | $6.30 |
| Average True Range (ATR) | 0.15 | 0.42 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 10.87 | 34.46 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.